BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chua H, Feng S, Lewnard JA, Sullivan SG, Blyth CC, Lipsitch M, Cowling BJ. The Use of Test-negative Controls to Monitor Vaccine Effectiveness: A Systematic Review of Methodology. Epidemiology 2020;31:43-64. [PMID: 31609860 DOI: 10.1097/EDE.0000000000001116] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 19.0] [Reference Citation Analysis]
Number Citing Articles
1 Lewnard JA. Uses of pathogen detection data to estimate vaccine direct effects in case-control studies. J R Soc Interface 2020;17:20200161. [PMID: 32781936 DOI: 10.1098/rsif.2020.0161] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
2 Britton A, Fleming-Dutra KE, Shang N, Smith ZR, Dorji T, Derado G, Accorsi EK, Ajani UA, Miller J, Schrag SJ, Verani JR. Association of COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination and Delta Variant Predominance. JAMA 2022;327:1032-41. [PMID: 35157002 DOI: 10.1001/jama.2022.2068] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
3 Patel MM, Jackson ML, Ferdinands J. Postlicensure Evaluation of COVID-19 Vaccines. JAMA 2020;324:1939-40. [PMID: 33064144 DOI: 10.1001/jama.2020.19328] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
4 Hashan MR, Chapman G, Walker J, Jayne Davidson S, Auriac J, Smoll N, Kirk M, Akbar D, Booy R, Khandaker G. Protocol on establishing a prospective enhanced surveillance of vaccine preventable diseases in residential aged care facilities in Central Queensland, Australia: an observational study. BMJ Open 2022;12:e060407. [DOI: 10.1136/bmjopen-2021-060407] [Reference Citation Analysis]
5 Meites E, Bajema KL, Kambhampati A, Prill M, Marconi VC, Brown ST, Rodriguez-Barradas MC, Beenhouwer DO, Holodniy M, Lucero-Obusan C, Cardemil C, Cates J, Surie D. Adapting the Surveillance Platform for Enteric and Respiratory Infectious Organisms at United States Veterans Affairs Medical Centers (SUPERNOVA) for COVID-19 Among Hospitalized Adults: Surveillance Protocol. Front Public Health 2021;9:739076. [PMID: 34778173 DOI: 10.3389/fpubh.2021.739076] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Fleming-Dutra KE, Britton A, Shang N, Derado G, Link-Gelles R, Accorsi EK, Smith ZR, Miller J, Verani JR, Schrag SJ. Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance. JAMA 2022. [PMID: 35560036 DOI: 10.1001/jama.2022.7493] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Blyth CC, Britton KJ, Nguyen CD, Sapura J, Kave J, Nivio B, Chan J, Satzke C, Ford R, Kirarock W, Lehmann D, Pomat W, Russell FM. Effectiveness of 13-valent pneumococcal conjugate vaccine against hypoxic pneumonia and hospitalisation in Eastern Highlands Province, Papua New Guinea: An observational cohort study. Lancet Reg Health West Pac 2022;22:100432. [PMID: 35308576 DOI: 10.1016/j.lanwpc.2022.100432] [Reference Citation Analysis]
8 Kuitunen I, Uimonen M, Seppälä SJ, Ponkilainen VT. COVID-19 vaccination status and testing rates in Finland-A potential cause for bias in observational vaccine effectiveness analysis. Influenza Other Respir Viruses 2022. [PMID: 35475567 DOI: 10.1111/irv.12993] [Reference Citation Analysis]
9 Cates JE, Amin AB, Tate JE, Lopman B, Parashar U. Do Rotavirus Strains Affect Vaccine Effectiveness? A Systematic Review and Meta-analysis. Pediatr Infect Dis J 2021;40:1135-43. [PMID: 34870393 DOI: 10.1097/INF.0000000000003286] [Reference Citation Analysis]
10 Norman DA, Cheng AC, Macartney KK, Moore HC, Danchin M, Seale H, McRae J, Clark JE, Marshall HS, Buttery J, Francis JR, Crawford NW, Blyth CC. Influenza hospitalizations in Australian children 2010-2019: The impact of medical comorbidities on outcomes, vaccine coverage, and effectiveness. Influenza Other Respir Viruses 2021. [PMID: 34787369 DOI: 10.1111/irv.12939] [Reference Citation Analysis]
11 Lipsitch M, Krammer F, Regev-Yochay G, Lustig Y, Balicer RD. SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. Nat Rev Immunol 2021. [PMID: 34876702 DOI: 10.1038/s41577-021-00662-4] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
12 Feldstein LR, Self WH, Ferdinands JM, Randolph AG, Aboodi M, Baughman AH, Brown SM, Exline MC, Files DC, Gibbs K, Ginde AA, Gong MN, Grijalva CG, Halasa N, Khan A, Lindsell CJ, Newhams M, Peltan ID, Prekker ME, Rice TW, Shapiro NI, Steingrub J, Talbot HK, Halloran ME, Patel M; Influenza Vaccine Effectiveness in the Critically Ill (IVY) Investigators and the Pediatric Intensive Care Influenza Vaccine Effectiveness (PICFLU-VE) Investigators. Incorporating Real-time Influenza Detection Into the Test-negative Design for Estimating Influenza Vaccine Effectiveness: The Real-time Test-negative Design (rtTND). Clin Infect Dis 2021;72:1669-75. [PMID: 32974644 DOI: 10.1093/cid/ciaa1453] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Zhang L, Wei M, Jin P, Li J, Zhu F. An evaluation of a test-negative design for EV-71 vaccine from a randomized controlled trial. Hum Vaccin Immunother 2021;17:2101-6. [PMID: 33529093 DOI: 10.1080/21645515.2020.1859900] [Reference Citation Analysis]
14 Liu C, Lee J, Ta C, Soroush A, Rogers J, Kim JH, Natarajan K, Zucker J, Perl Y, Weng C. A Retrospective Analysis of Risk Factors Associated with the SARS-CoV-2 Breakthrough in Fully mRNA Vaccinated Individuals. JMIR Public Health Surveill 2022. [PMID: 35486806 DOI: 10.2196/35311] [Reference Citation Analysis]
15 Ioannou GN, Locke ER, O'Hare AM, Bohnert ASB, Boyko EJ, Hynes DM, Berry K. COVID-19 Vaccination Effectiveness Against Infection or Death in a National U.S. Health Care System : A Target Trial Emulation Study. Ann Intern Med 2021. [PMID: 34928700 DOI: 10.7326/M21-3256] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 7.0] [Reference Citation Analysis]
16 Liu C, Lee J, Ta C, Soroush A, Rogers JR, Kim JH, Natarajan K, Zucker J, Weng C. A Retrospective Analysis of COVID-19 mRNA Vaccine Breakthrough Infections - Risk Factors and Vaccine Effectiveness. medRxiv 2021:2021. [PMID: 34642696 DOI: 10.1101/2021.10.05.21264583] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 16.0] [Reference Citation Analysis]
17 Ciocănea-Teodorescu I, Nason M, Sjölander A, Gabriel EE. Adjustment for Disease Severity in the Test-Negative Study Design. Am J Epidemiol 2021;190:1882-9. [PMID: 33728441 DOI: 10.1093/aje/kwab066] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Accorsi EK, Britton A, Fleming-Dutra KE, Smith ZR, Shang N, Derado G, Miller J, Schrag SJ, Verani JR. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. JAMA 2022;327:639-51. [PMID: 35060999 DOI: 10.1001/jama.2022.0470] [Cited by in Crossref: 111] [Cited by in F6Publishing: 43] [Article Influence: 111.0] [Reference Citation Analysis]
19 Chambers C. Using observational epidemiology to evaluate COVID-19 vaccines: integrating traditional methods with new data sources and tools. Can J Public Health 2021. [PMID: 34160784 DOI: 10.17269/s41997-021-00554-z] [Reference Citation Analysis]
20 Dufault SM, Jewell NP. Analysis of counts for cluster randomized trials: Negative controls and test-negative designs. Stat Med 2020;39:1429-39. [PMID: 31998994 DOI: 10.1002/sim.8488] [Cited by in F6Publishing: 1] [Reference Citation Analysis]